A randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m2 Q 21 days x 3 courses plus low dose paclitaxel 40 mg/m2/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m2 Q 21 days x 3 courses plus observation in patients with early stage ovarian carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2019 Biomarkers information updated
- 27 Apr 2011 Results published in the Gynecologic Oncology.
- 13 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.